Download PDF
Horm Metab Res 2003; 35(5): 296-300
DOI: 10.1055/s-2003-41305
Original Clinical
© Georg Thieme Verlag Stuttgart · New York

Metabolic Profile in Patients with Benign Prostate Hyperplasia or Prostate Cancer and Normal Glucose Tolerance

P.  F.  Zamboni1 , M.  Simone2 , A.  Passaro1 , E.  Doh  Dalla Nora1 , R.  Fellin1 , A.  Solini3
  • 1 Section of Internal Medicine II, University of Ferrara
  • 2 Division of Urology, Arcispedale S. Anna Ferrara
  • 3 Department of Internal Medicine, University of Pisa, Italy
Further Information

Publication History

Received 25 July 2002

Accepted after Revision 8 November 2002

Publication Date:
13 August 2003 (online)

Also available at
    Permissions and Reprints

Abstract

Familial predisposition together with several environmental factors may be involved in the pathogenesis of common prostate disease such as benign hypertrophy or prostate neoplasm. A higher incidence of both these conditions has been described in some insulin-resistant states such as obesity, but not much information is available on the effect of metabolic profile on gland morphology. The aim of this study was to evaluate the relation between glucose and lipid pattern and prostate diameters in two groups of non-diabetic individuals with benign prostate hypertrophy or cancer. 109 patients were recruited; plasma glucose, lipids and hormonal profile as well as an ultrasonographic evaluation of the gland volume and diameters were determined. Patients with prostate cancer had significantly higher levels of insulin and were more insulin resistant; in contrast, in subjects with prostate hypertrophy, fasting plasma glucose and - to a lesser extent - serum triglycerides emerged as the main determinants of gland volume. These observations may indicate that an improvement of insulin sensitivity and strategies to maintain a strict glucose and lipid control even in non-diabetic subjects are useful objectives in the prevention of prostate diseases.

Key words

Prostate Volume - OGTT - PSA - Lipid Pattern

References

  • 1 Borre M, Nerstrom B, Overgaard J. The natural history of prostate carcinoma based on a Danish population treated with no intent to cure.  Cancer. 1997;  80 917-928
    CrossrefPubMedGoogle Scholar
  • 2 Parkin D M, Pisani P, Ferlay J. Global cancer statistics.  CA Cancr J Clin. 1999;  49 33-64
    CrossrefPubMedGoogle Scholar
  • 3 Hekman P. Genetic and environmental factors in prostate cancer genesis: identifying high-risk cohorts.  Eur Urol. 1999;  35 362-369
    CrossrefPubMedGoogle Scholar
  • 4 Gao J, Arnold J T, Isaacs J T. Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells.  Cancer Res. 2001;  61 5038-5044
    PubMedGoogle Scholar
  • 5 Asamoto M, Hokaiwado N, Cho Y M, Takahashi S, Ikeda Y, Imaida K, Shirai T. Prostate carcinomas developing in transgenic rats with SV40 T antigen expression under probasin promoter control are strictly androgen dependent.  Cancer Res. 2001;  61 4693-4700
    PubMedGoogle Scholar
  • 6 Nomura A M, Kolonel L N. Prostate cancer: a current perspective.  Epidemiol Rev. 1991;  13 200-207
    PubMedGoogle Scholar
  • 7 Sciarra F, Toscano V. Role of estrogens in human benign prostatic hyperplasia.  Arch Androl. 2000;  44 213-222
    PubMedGoogle Scholar
  • 8 Muir C S, Nectoux J, Staszewski J. The epidemiology of prostatic cancer: geographical distribution and time trends.  Acta Oncol. 1991;  30 133-140
    CrossrefPubMedGoogle Scholar
  • 9 Chan J M, Stampfer M J, Giovannucci E, Gann P H, Ma J, Wilkinson P, Hennekens C H, Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study.  Science. 1998;  279 563-566
    CrossrefPubMedGoogle Scholar
  • 10 Pollak M. Insulin-like growth factors and prostate cancer.  Epidemiol Rev. 2001;  23 59-66
    PubMedGoogle Scholar
  • 11 Putnam S D, Cerhan J R, Parker A S, Bianchi G D, Wallace R B, Cantor K P, Lynch C F. In white men obesity is a risk factor for more clinically significant prostate cancer.  Ann Epidemiol. 2000;  10 361-369
    CrossrefPubMedGoogle Scholar
  • 12 Hsing A W, Deng J, Sesterhenn I A, Mostofi F K, Stanczyk F Z, Benichou J, Xie T, Gao Y T. Body size and prostate cancer: a population-based case-control study in China.  Cancer Epidemiol Biomarkers Prev. 2000;  9 1335-1341
    PubMedGoogle Scholar
  • 13 Will J C, Vinicor F, Calle E E. Is diabetes mellitus associated with prostate cancer incidence and survival?.  Epidemiology. 1999;  10 313-318
    PubMedGoogle Scholar
  • 14 Gapstur S M, Gann P H, Colangelo L A, Barron-Simpson R, Kopp P, Dyer A, Liu K. Postload plasma glucose concentration and 27-year prostate cancer mortality (United States).  Cancer Causes Control. 2001;  12 763-772
    CrossrefPubMedGoogle Scholar
  • 15 Meigs J B, Mohr B, Barry M J, Collins M M, Mc Kinlay J B. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men.  J Clin Epidemiol. 2001;  54 935-944
    CrossrefPubMedGoogle Scholar
  • 16 Lee E, Park M S, Shin C, Lee H, Yoo K, Kim Y, Shin Y, Paik H Y, Lee C. A high-risk group for prostatism: a population-based epidemiological study in Korea.  Br J Urol. 1997;  79 736-741
    PubMedGoogle Scholar
  • 17 Matthews D R, Hosker J P, Rudenski A S, Naylor B A, Treacher D F, Turner R C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.  Diabetologia. 1985;  28 412-419
    Google Scholar
  • 18 Collins G N, Raab G M, Hehir M, King B, Garraway W M. Reproducibility and observer variability of transrectal ultrasound measurements of prostatic volume.  Ultrasound Med Biol. 1995;  21 1101-1105
    CrossrefPubMedGoogle Scholar
  • 19 Bourke J B, Chir B, Griffin J P. Hypertension, diabetes and blood groups in benign prostatic hypertrophy.  Br J Urol. 1966;  38 18-23
    PubMedGoogle Scholar
  • 20 Hammarsten J, Hogstedt B. Hyperinsulinemia as a risk factor for developing benign prostatic hyperplasia.  Eur Urol. 2001;  39 151-158
    CrossrefPubMedGoogle Scholar
  • 21 Giovannucci E, Rimm E B, Stampfer M J, Colditz G A, Willett W C. Diabetes mellitus and risk of prostate cancer.  Cancer Causes Control. 1998;  9 3-9
    CrossrefPubMedGoogle Scholar
  • 22 Moore M A, Park C B, Tsuda H. Implications of the hyperinsulinaemia-diabetes-cancer link for preventive efforts.  Eur J Cancer Prev. 1998;  7 89-107
    PubMedGoogle Scholar
  • 23 Nakamura J, Kasuya Y, Hamada Y, Nakashima E, Naruse K, Yasuda Y, Kato K, Hotta N. Glucose-induced hyperproliferation of cultured rat aortic smooth muscle cells through polyol pathway hyperactivity.  Diabetologia. 2001;  44 480-487
    CrossrefPubMedGoogle Scholar
  • 24 Singh G, Lakkis C L, Laucirica R, Epner D E. Regulation of prostate cancer cell division by glucose.  J Cell Physiol. 1999;  180 431-438
    CrossrefPubMedGoogle Scholar
  • 25 Tymchuk C N, Barnard R J, Hebr D, Aronson W J. Evidence of an inhibitory effect of diet and exercise on prostate cancer cell growth.  J Urol. 2001;  166 1185-1189
    CrossrefPubMedGoogle Scholar
  • 26 Cohen P. Serum insulin-like growth factor-I levels and prostate cancer risk: interpreting the evidence.  J Natl Cancer Inst. 1998;  90 876-879
    CrossrefPubMedGoogle Scholar
  • 27 Iwamura M, Sluss P M, Casamento J B, Cockett A T. Insulin like growth factor I: action and receptor characterization in human prostate cancer cell lines.  Prostate. 1993;  22 243-252
    PubMedGoogle Scholar
  • 28 Leherer S, Diamond E J, Stagger S, Stone N N, Stock R G. Increased serum insulin associated with increased risk of prostate cancer recurrence.  Prostate. 2002;  50 1-3
    CrossrefPubMedGoogle Scholar
  • 29 Shaneyfelt T, Husein R, Bubley G, Mantzoros C S. Hormonal predictor of prostate cancer: a meta-analysis.  J Clin Oncol. 2000;  18 847-853
    PubMedGoogle Scholar
  • 30 Haffner S M. Sex hormone-binding protein, hyperinsulinemia, insulin resistance and non insulin dependent diabetes.  Horm Res. 1996;  45 233-237
    PubMedGoogle Scholar
  • 31 Pasquali R, Casimirri F, De Iasio R, Mesini P, Boschi S, Chierici R, Flamia R, Biscotti M, Vicennati V. Insulin regulates testosterone and sex-hormone-binding globulin concentrations in adult normal-weight and obese men.  J Clin Endocrinol Metab. 1995;  80 654-658
    CrossrefPubMedGoogle Scholar
  • 32 Loukovaara M, Carson M, Adlercreutz H. Regulation of production and secretion of sex hormone-binding globulin in HepG2 cell cultures by hormones and growth factors.  J Clin Endocrinol Metab. 1995;  80 160-164
    CrossrefPubMedGoogle Scholar
  • 33 Hammarsten J, Hogstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia.  Blood Press. 1999;  8 29-36
    CrossrefPubMedGoogle Scholar
  • 34 Kirby R S. Clinical pharmacology of alpha1-adrenoceptor antagonists.  Eur Urol. 1999;  36 48-53
    PubMedGoogle Scholar
  • 35 Dickerman R D, McConathy W J, Zachariah N Y. Testosterone, sex-hormone-binding globulin, lipoproteins, and vascular disease risk.  J Cardiovasc Risk. 1997;  4 363-366
    PubMedGoogle Scholar
  • 36 Hislop M S, StClair Gibson A, Lambert M I, Noakes T D, Marais A D. Effect of androgen manipulation on postprandial triglyceridemia, low-density lipoprotein particle size and lipoprotein(a) in men.  Atherosclerosis. 2001;  59 425-432
    PubMedGoogle Scholar
  • 37 Bhasin S, Woodhouse L, Casaburi R, Singh A B, Bhasin D, Berman N, Chen X, Yarasheski K E, Magliano L, Dzekov C, Dzekov J, Bross R, Phillips J, Sinha-Hikim I, Shen R, Storer T W. Testosterone dose-response relationships in healthy young men.  Am J Physiol. 2001;  28 E1172-E1181
    PubMedGoogle Scholar
  • 38 Pugeat M, Moulin P, Cousin P, Fimbel S, Nicolas M H, Crave J C, Lejeune H. Interrelations between sex hormone-binding globulin (SHBG), plasma lipoproteins and cardiovascular risk.  J Steroid Biochem Mol Biol. 1995;  53 567-572
    CrossrefPubMedGoogle Scholar
  • 39 Goodman-Gruen D, Barrett-Connor E. Sex differences in the association of endogenous sex hormone levels and glucose tolerance status in older men and women.  Diabetes Care. 2000;  23 912-918
    CrossrefPubMedGoogle Scholar
  • 40 Oh J Y, Barrett-Connor E, Wedick N M, Wingard D L. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study.  Diabetes Care. 2002;  25 55-60
    CrossrefPubMedGoogle Scholar
  • 41 Satariano W A, Ragland K E, van den Eeen S K. Causes of death in men diagnosed with prostate carcinoma.  Cancer. 1998;  83 1180-1188
    CrossrefPubMedGoogle Scholar

A. Solini, M.D. 

Department of Internal Medicine University of Pisa · Section of Internal Medicine III ·

Via Roma 67 · 56100 Pisa

Phone: +39(050)993482

Fax: +39(050)553235

Email: a.solini@int.med.unipi.it

      >